Last reviewed · How we verify

Intravenous (IV) zanamivir — Competitive Intelligence Brief

Intravenous (IV) zanamivir (Intravenous (IV) zanamivir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease.

phase 3 Neuraminidase inhibitor Influenza virus neuraminidase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous (IV) zanamivir (Intravenous (IV) zanamivir) — GlaxoSmithKline. Zanamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells by inhibiting the viral neuraminidase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Intravenous (IV) zanamivir TARGET Intravenous (IV) zanamivir GlaxoSmithKline phase 3 Neuraminidase inhibitor Influenza virus neuraminidase
Relenza ZANAMIVIR GSK marketed Neuraminidase Inhibitor [EPC] Sialidase 3 1999-01-01
Oseltamivir phosphate granules Oseltamivir phosphate granules China Academy of Chinese Medical Sciences marketed Neuraminidase inhibitor Influenza neuraminidase
oseltamivir and chinese medicinal herbs oseltamivir and chinese medicinal herbs Capital Medical University marketed Neuraminidase inhibitor combined with herbal supplement Influenza viral neuraminidase; herbal targets unknown
Oseltamivir Phosphate For Oral Suspension Oseltamivir Phosphate For Oral Suspension The Affiliated Hospital of Qingdao University marketed Neuraminidase inhibitor Influenza neuraminidase
Oseltamivir(oral) Oseltamivir(oral) Guangdong Raynovent Biotech Co., Ltd marketed Neuraminidase inhibitor Influenza neuraminidase
Tamiflu (verum) Tamiflu (verum) National Institute for Public Health and the Environment (RIVM) marketed Neuraminidase inhibitor Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

  1. University of Oxford · 2 drugs in this class
  2. GlaxoSmithKline · 2 drugs in this class
  3. Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
  4. UMC Utrecht · 2 drugs in this class
  5. Genuine Research Center, Egypt · 1 drug in this class
  6. The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
  7. China Academy of Chinese Medical Sciences · 1 drug in this class
  8. Hoffmann-La Roche · 1 drug in this class
  9. National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
  10. The Affiliated Hospital of Qingdao University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous (IV) zanamivir — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-iv-zanamivir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: